Lindbrook Capital LLC Buys Shares of 431 Revvity, Inc. (NYSE:RVTY)

Lindbrook Capital LLC purchased a new position in Revvity, Inc. (NYSE:RVTY) during the fourth quarter, Holdings Channel reports. The fund purchased 431 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Gladius Capital Management LP boosted its holdings in shares of Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares in the last quarter. CENTRAL TRUST Co bought a new stake in shares of Revvity in the 4th quarter worth approximately $27,000. ORG Partners LLC purchased a new stake in shares of Revvity in the 4th quarter valued at $32,000. JTC Employer Solutions Trustee Ltd bought a new position in shares of Revvity during the 4th quarter valued at $33,000. Finally, Desjardins Global Asset Management Inc. bought a new stake in Revvity in the fourth quarter worth $37,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.60% of the stock is currently owned by company insiders.

Revvity Trading Down 0.6 %

RVTY opened at $102.09 on Friday. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $132.54. The stock has a market cap of $12.61 billion, a PE ratio of 18.56, a PEG ratio of 2.69 and a beta of 1.09. The business has a 50 day moving average of $104.68 and a 200-day moving average of $101.50.

Revvity (NYSE:RVTY) last announced its earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. The firm had revenue of $695.90 million for the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. Equities research analysts predict that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. Revvity’s dividend payout ratio (DPR) is presently 5.09%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Evercore ISI upgraded Revvity from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Stifel Nicolaus lifted their target price on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. Raymond James raised their price target on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. KeyCorp upped their price objective on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Finally, Barclays increased their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.